ABX-CRO and ITM (Isotope Technologies Munich) win the prestigious Marie Curie Award of the EANM for outstanding research contributions in nuclear medicine: Dosimetry of the COMPETE study (ITM-11 (n.c.a. 177Lu-DOTATOC) in GEP-NET)
The COMPETE (Controlled, Open-label, Multicentre phase III study to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to targeted molecular therapy with Everolimus in NET) study, is the globally first ever conducted prospective RCT to include comprehensive tumour and safety dosimetry in all patients.
The study, designed by Dr. Andreas Kluge and dosimetrically analysed by the ABX-CRO ICL team featured central quantitative reconstruction of 177Lu-SPECT of data from more than 50 SPECT scanners world-wide, double contouring segmentation (CT for lesion volume and spill-out corrected SPECT segmentation), planar and hybrid dosimetry as well as full 3D dosimetry in a subgroup for comparison.
The data lay the ground for understanding the absorbed dose – response relationship in NET, and will allow to generate a convenient, patient-friendly single time point dosimetry protocol for future clinical routine use. The generated data will also allow to pave the way for an individually optimised PRRT approach in the management of GEP-NETs.